07:20 AM EDT, 06/17/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that the US Food and Drug Administration has approved Imfinzi combined with chemotherapy followed by Imfinzi monotherapy to treat adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.

The company said the approval was based on phase 3 data showing the therapy cut the risk of disease progression or death by 58% compared with chemotherapy alone.

The combination therapy's safety and tolerability was "generally manageable, well-tolerated and broadly consistent" with previous data with no new safety signals, the company added.

Price: 79.12, Change: -0.47, Percent Change: -0.59